
EquitySector - HealthcareVery High Risk
Regular
NAV (12-Jun-26)
Returns (Since Inception)
Fund Size
₹603 Cr
Expense Ratio
2.57%
ISIN
INF03VN01878
Minimum SIP
₹500
Exit Load
No Charges
Inception Date
06 Feb 2024
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+14.48%
+9.02% (Cat Avg.)
Since Inception
+19.90%
— (Cat Avg.)
| Equity | ₹597.92 Cr | 99.17% |
| Others | ₹5.01 Cr | 0.83% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹63.12 Cr | 10.47% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹39.46 Cr | 6.54% |
| Cash Offset For Derivatives | Cash - General Offset | ₹-37.86 Cr | 6.28% |
| Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹27.54 Cr | 4.57% |
| Laurus Labs Ltd | Equity | ₹24.88 Cr | 4.13% |
| Fortis Healthcare Ltd | Equity | ₹24.86 Cr | 4.12% |
| Divi's Laboratories Ltd | Equity | ₹24.75 Cr | 4.11% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹24.27 Cr | 4.02% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹20.57 Cr | 3.41% |
| Aurobindo Pharma Ltd | Equity | ₹20.1 Cr | 3.33% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹19.94 Cr | 3.31% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹18.84 Cr | 3.13% |
| Sai Life Sciences Ltd | Equity | ₹18.19 Cr | 3.02% |
| Lupin Ltd | Equity | ₹17.88 Cr | 2.97% |
| Neuland Laboratories Ltd | Equity | ₹15.94 Cr | 2.64% |
| Acutaas Chemicals Ltd | Equity | ₹14.74 Cr | 2.45% |
| Corona Remedies Ltd | Equity | ₹14.63 Cr | 2.43% |
| Aurobindo Pharma Limited | Equity - Future | ₹12.06 Cr | 2.00% |
| Thyrocare Technologies Ltd | Equity | ₹11.93 Cr | 1.98% |
| Dr. Reddy's Laboratories Limited | Equity - Future | ₹11.89 Cr | 1.97% |
| Narayana Hrudayalaya Ltd | Equity | ₹11.66 Cr | 1.93% |
| Emcure Pharmaceuticals Ltd | Equity | ₹11.05 Cr | 1.83% |
| Rainbow Childrens Medicare Ltd | Equity | ₹10.82 Cr | 1.79% |
| Ajanta Pharma Ltd | Equity | ₹10.74 Cr | 1.78% |
| Aether Industries Ltd | Equity | ₹9.39 Cr | 1.56% |
| Navin Fluorine International Ltd | Equity | ₹8.7 Cr | 1.44% |
| OneSource Specialty Pharma Ltd | Equity | ₹7.97 Cr | 1.32% |
| Shaily Engineering Plastics Ltd | Equity | ₹7.91 Cr | 1.31% |
| Dr. Lal PathLabs Ltd | Equity | ₹7.75 Cr | 1.29% |
| Strides Pharma Science Ltd | Equity | ₹7.63 Cr | 1.27% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹7.53 Cr | 1.25% |
| Kovai Medical Center & Hospital Ltd | Equity | ₹7.52 Cr | 1.25% |
| Pfizer Ltd | Equity | ₹7.51 Cr | 1.24% |
| Poly Medicure Ltd | Equity | ₹7.41 Cr | 1.23% |
| Zydus Lifesciences Ltd | Equity | ₹6.86 Cr | 1.14% |
| Ipca Laboratories Ltd | Equity | ₹6.16 Cr | 1.02% |
| Aarti Pharmalabs Ltd | Equity | ₹5.78 Cr | 0.96% |
| AstraZeneca Pharma India Ltd | Equity | ₹5.71 Cr | 0.95% |
| Senores Pharmaceuticals Ltd | Equity | ₹5.14 Cr | 0.85% |
| Tbill | Bond - Gov't/Treasury | ₹4.99 Cr | 0.83% |
| Day Tbill | Bond - Gov't/Treasury | ₹4.98 Cr | 0.83% |
| Future on Divi's Laboratories Ltd | Equity - Future | ₹4.77 Cr | 0.79% |
| Sudeep Pharma Ltd | Equity | ₹4.45 Cr | 0.74% |
| Supriya Lifescience Ltd | Equity | ₹4.4 Cr | 0.73% |
| Anthem Biosciences Ltd | Equity | ₹4.38 Cr | 0.73% |
| Innova Captab Ltd | Equity | ₹4.17 Cr | 0.69% |
| Mankind Pharma Limited | Equity - Future | ₹4.05 Cr | 0.67% |
| Zota Health Care Ltd | Equity | ₹3.78 Cr | 0.63% |
| Procter & Gamble Health Ltd | Equity | ₹3.69 Cr | 0.61% |
| Mankind Pharma Ltd | Equity | ₹2.99 Cr | 0.50% |
| Max Healthcare Institute Limited | Equity - Future | ₹2.26 Cr | 0.37% |
| Cohance Lifesciences Ltd | Equity | ₹2.02 Cr | 0.33% |
| Tbill | Bond - Gov't/Treasury | ₹1.99 Cr | 0.33% |
| Apollo Hospitals Enterprise Limited | Equity - Future | ₹1.82 Cr | 0.30% |
| Tatva Chintan Pharma Chem Ltd | Equity | ₹1.47 Cr | 0.24% |
| Orchid Pharma Ltd | Equity | ₹1.39 Cr | 0.23% |
| Tbill | Bond - Gov't/Treasury | ₹1 Cr | 0.17% |
| Tbill | Bond - Gov't/Treasury | ₹1 Cr | 0.17% |
| India (Republic of) | Bond - Short-term Government Bills | ₹1 Cr | 0.17% |
| Tbill | Bond - Gov't/Treasury | ₹0.8 Cr | 0.13% |
| Net Receivables / (Payables) | Cash | ₹-0.61 Cr | 0.10% |
| Sun Pharmaceutical Industries Limited | Equity - Future | ₹0.57 Cr | 0.09% |
| Fortis Healthcare Limited | Equity - Future | ₹0.43 Cr | 0.07% |
| Tbill | Bond - Gov't/Treasury | ₹0.2 Cr | 0.03% |
Large Cap Stocks
22.70%
Mid Cap Stocks
23.27%
Small Cap Stocks
47.71%
AAA
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹517.85 Cr | 85.89% |
| Basic Materials | ₹42.21 Cr | 7.00% |
Standard Deviation
This fund
--
Cat. avg.
16.65%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
1.03
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.84
Higher the better

Since February 2024

Since February 2024
Since May 2025
Since February 2024
Since January 2025
ISIN INF03VN01878 | Expense Ratio 2.57% | Exit Load No Charges | Fund Size ₹603 Cr | Age 2 years 4 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹36,501 Cr
Address
1&2 Senapati Bapat Marg, Elphinstone Road (West) Mumbai Mumbai City, Mumbai
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments